All In Biotech

NDA 016267 · Mitem Pharma

Desferal

Deferoxamine Mesylate · Injection

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Sep 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1968

Apr 1, 1968

Approved uses

2

Original approval plus efficacy supplements

Registered trials

70

14 Phase 3, 8 recruiting

FAERS reports

1,676

1,487 serious, 334 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 2, 2025.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 4, 1979 Supplement 11 · Efficacy
  • Apr 1, 1968 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • DESFERAL · DEFEROXAMINE MESYLATE 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • DESFERAL · DEFEROXAMINE MESYLATE 500MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Deferoxamine" as an intervention, any sponsor and status, largest first.

All 70 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • serum ferritin increased157
  • pyrexia116
  • diarrhoea105
  • haemoglobin decreased101
  • off label use100
  • vomiting90
  • nausea87
  • death85
  • fatigue76
  • drug ineffective75
  • dyspnoea73
  • blood creatinine increased71

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200426
200527
200661
200749
200870
200986
201075
2011102
2012128
201363
201498
201595
2016111
2017114
201877
201974
202066
202134
202281
202362
202467
202560
202649

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 193 on PubMed

Sponsor: Mitem Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.